Dok Hyun Yoon
University of Ulsan
322 Papers
862 Citations
Dok Hyun Yoon is an academic researcher from University of Ulsan. The author has contributed to research in topics: Medicine & Internal medicine. The author has an hindex of 30, co-authored 247 publications.
Chat about Author
Papers
Interim Results of the Phase 1 Study of Tnb-486, a Novel CD19xCD3 T-Cell Engager, in Patients with Relapsed/Refractory (R/R) B-NHL
Jing-Zhou Hou,Ryan Jacobs,Seok-Goo Cho,Sumana Devata,Sameh Gaballa,Dok Hyun Yoon,Don A. Stevens,Jin-Soo Kim,Ben Buelow,Ranjit Nair +9 more
TL;DR: In this article , the authors presented the interim results of the ongoing FIH phase 1 study of TNB-486 in R/R B-NHL, where the primary objectives were to assess the safety, tolerability and pharmacokinetics of the drug when administered as monotherapy and to determine the optimal biologically active dose.
11
LGALS3 as a prognostic factor for classical Hodgkin’s lymphoma
TL;DR: It is suggested that LGALS3 is an independent prognostic factor in classical Hodgkin’s lymphoma, and may allow the identification of a subgroup of patients with limited-stage classical Hodgkins’ lymphoma who require more intensive therapy.
11
Expression of CD99 in Multiple Myeloma: A Clinicopathologic and Immunohistochemical Study of 170 Cases
Su Jin Shin,Hyangsin Lee,Geunyoung Jung,Minchan Gil,Hosub Park,Young Soo Park,Dok Hyun Yoon,Cheolwon Suh,Chan Jeoung Park,Jooryung Huh,Chan-Sik Park +10 more
TL;DR: Investigation of the role of CD99, a transmembrane protein highly expressed in many hematopoietic cells including subpopulations of normal and neoplastic plasma cells, for MM risk stratification suggested that CD99 may be a helpful immunohistochemical marker for risk Stratification.
Cpi-818, an Oral Interleukin-2-Inducible T-Cell Kinase Inhibitor, Is Well-Tolerated and Active in Patients with T-Cell Lymphoma
Michael S. Khodadoust,Tatyana Feldman,Dok Hyun Yoon,Costas K. Yannakou,Dejan Radeski,Youn H. Kim,Neha Mehta-Shah,Amit Khot,Ryan A. Wilcox,Won Seog Kim,Steven M. Horwitz,Joseph J. Buggy,Andrew Hotson,Craig M. Hill,Brian Munneke,Suresh Mahabhashyam,Richard A. Miller,James W. Janc,Mehrdad Mobasher +18 more
TL;DR: Michael S. Khodadoust, MD, PhD1, Tatyana A. Feldman, MD2, Dok Hyun Yoon,MD, PhD3, Costas K. Yannakou, MBBS (Hons), FRACP, FRCPA4, Dejan Radeski,MBBS, FRACP-FRCPA5, Youn H. Kim, MD6, Neha Mehta-Shah, MD
10
Thiotepa, busulfan, and cyclophosphamide or busulfan, cyclophosphamide, and etoposide high-dose chemotherapy followed by autologous stem cell transplantation for consolidation of primary central nervous system lymphoma.
Jaewon Hyung,Jung Yong Hong,Dok Hyun Yoon,Shin Kim,Jung Sun Park,Chan-Sik Park,Sang-wook Lee,Jeong Hoon Kim,Jin-Sook Ryu,Jooryung Huh,Cheolwon Suh +10 more
TL;DR: Despite the greater incidence of adverse events, TBC showed better outcomes than BuCyE in terms of survival, and the incidence of oral mucositis, nausea, and vomiting was higher with TBC than Bu CyE.
10